Finance

Lists
Outlook: 87.5% bullish·0.0% bearish
Go to analysis
AMRX:NASDAQ
Amneal Pharmaceuticals Inc
၂၁.၂၃ US$
-၀.၇၀%
(-၀.၁၅) 1D
၂၁.၂၃ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: နို ၁၆, GMT-၅ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMRX...
Open
၂၁.၄၇ US$
High
၂၁.၆၀ US$
Low
၂၁.၁၀ US$
Mkt. cap
၇၃၉.၆၈ ဋေ
Avg. vol.
၄.၀၀ သန်း
Volume
၂.၀၀
P/E ratio
၅၂.၁၃
52-wk high
၂၂.၀၇ US$
52-wk low
၁၁.၃၉ US$
EPS
၀.၄၁ US$
Beta
၁.၂၄
Shares outstanding
၃၄.၈၄ ကုဋေ
No. of employees
၉ ထောင်
Open
၂၁.၄၇ US$
High
၂၁.၆၀ US$
Low
၂၁.၁၀ US$
Mkt. cap
၇၃၉.၆၈ ဋေ
Avg. vol.
၄.၀၀ သန်း
Volume
၂.၀၀
P/E ratio
၅၂.၁၃
52-wk high
၂၂.၀၇ US$
52-wk low
၁၁.၃၉ US$
EPS
၀.၄၁ US$
Beta
၁.၂၄
Shares outstanding
၃၄.၈၄ ကုဋေ
No. of employees
၉ ထောင်
News stories
From web sources and news partners
Zacks
Zacks
·
ပြီးခဲ့သည့် ၁၆ နာရီ
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
Profile
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States. Wikipedia
About Amneal Pharmaceuticals Inc
CEOChintu Patel | Chirag Patel
Employees၈.၇ ထောင်
Founded၂၀၀၂
HeadquartersBridgewater, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websiteamneal.com
Analyst ratings
Based on 6 analysts giving stock ratings to AMRX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AMRX in the last 3 months.
Highest
Current ၂၁.၂၃ US$
၂၈.၀၀ US$ (+၃၁.၈၉%)
Average
၂၄.၈၃ US$ (+၁၆.၉၆%)
Lowest
၂၀.၀၀ US$ (-၅.၇၉%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ashwani Verma
UBS
Buy
Reiterated
၂၈.၀၀ US$
+၃၁.၉%
11/09/2026
Daniel Clark
Leerink Partners
Buy
Maintained
၂၅.၀၀ US$
+၁၇.၈%
11/05/2026
Chris Schott
J.P. Morgan
Buy
Maintained
၂၅.၀၀ US$
+၁၇.၈%
11/04/2026
Les Sulewski
Oppenheimer
Buy
Maintained
၂၇.၀၀ US$
+၂၇.၂%
11/03/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
၂၇.၀၀ US$
+၂၇.၂%
11/03/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
၂၄.၀၀ US$
+၁၃%
10/29/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
၂၄.၀၀ US$
+၁၃%
10/29/2026
Glen Santangelo
Barclays
Buy
Reiterated
၂၀.၀၀ US$
-၅.၈%
09/21/2026
David Amsellem
Piper Sandler
Buy
Reiterated
၁၇.၀၀ US$
-၁၉.၉%
07/20/2026
Last report
၂၀၂၆ နို ၃
Fiscal period
Q3 2026
၀.၂၆ US$ / ၀.၂၄ US$
+၉.၅၂%beat
Revenue / Est. (USD)
၈၆.၂၇ ကုဋေ / ၈၁.၇၉ ကုဋေ
+၅.၄၈%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၈၁.၄၃ ကုဋေ
၇၂.၂၅ ကုဋေ
၇၉.၆၂ ကုဋေ
၈၆.၂၇ ကုဋေ
Cost of goods sold
၅၁.၈၅ ကုဋေ
၄၀.၃၉ ကုဋေ
၄၆.၃၈ ကုဋေ
၅၃.၀၈ ကုဋေ
Cost of revenue
၅၁.၈၅ ကုဋေ
၄၀.၃၉ ကုဋေ
၄၆.၃၈ ကုဋေ
၅၃.၀၈ ကုဋေ
Research and development expenses
၃.၄၈ ကုဋေ
၃.၈၄ ကုဋေ
၃.၉၀ ကုဋေ
၆.၈၄ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၄.၆၅ ကုဋေ
၁၃.၈၉ ကုဋေ
၁၄.၈၇ ကုဋေ
၁၃.၉၆ ကုဋေ
Operating expense
၁၈.၁၃ ကုဋေ
၁၇.၇၂ ကုဋေ
၁၈.၆၄ ကုဋေ
၂၀.၇၄ ကုဋေ
Total operating expenses
၆၉.၉၈ ကုဋေ
၅၈.၁၁ ကုဋေ
၆၅.၀၂ ကုဋေ
၇၃.၈၁ ကုဋေ
Operating income
၁၁.၄၅ ကုဋေ
၁၄.၁၄ ကုဋေ
၁၄.၆၀ ကုဋေ
၁၂.၄၅ ကုဋေ
Other non operating income
၈.၇၆ သိန်း
၃.၀၈ သန်း
-၁.၇၉ သန်း
-၁.၂၅ ကုဋေ
EBT including unusual items
၅.၅၂ ကုဋေ
၈.၀၂ ကုဋေ
၇.၁၀ ကုဋေ
၁.၅၁ ကုဋေ
EBT excluding unusual items
၅.၇၇ ကုဋေ
၈.၃၃ ကုဋေ
၈.၇၂ ကုဋေ
၄.၉၉ ကုဋေ
Income tax expense
၅.၆၆ သန်း
၂.၁၈ သန်း
၁.၃၈ သန်း
၂.၇၅ သန်း
Effective tax rate
၁၀.၂၅%
၂.၇၁%
၁.၉၄%
၁၈.၂၇%
Other operating expenses
-၁.၀၀ ထောင်
-၆.၄၀ သောင်း
-၁.၃၀ သန်း
-၆.၃၁ သိန်း
Net income
၃.၅၁ ကုဋေ
၆.၂၃ ကုဋေ
၅.၇၇ ကုဋေ
-၂.၁၇ ကုဋေ
Net profit margin
၄.၃၁%
၈.၆၂%
၇.၂၄%
-၂.၅၁%
Earnings per share
၀.၂၁
၀.၂၇
၀.၃၀
၀.၂၆
Interest and investment income
-
-
-
-
Interest expense
-၅.၆၂ ကုဋေ
-၅.၃၄ ကုဋေ
-၅.၅၀ ကုဋေ
-၅.၈၉ ကုဋေ
Net interest expenses
-၅.၆၂ ကုဋေ
-၅.၃၄ ကုဋေ
-၅.၅၀ ကုဋေ
-၅.၈၉ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၁၆.၃၇ ကုဋေ
၁၈.၄၆ ကုဋေ
၁၉.၃၈ ကုဋေ
၁၇.၇၈ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ